

What is Amarin's perspective on the October 29th summary judgment ruling in the ongoing Vascepa® ANDA litigation?

We are pleased with the Court's summary judgment ruling on October 29th.

Seeking summary judgment at this stage in ANDA patent litigation is a common approach, for generics, to seek an early end to litigation and for both parties, to seek to limit the scope of issues at trial. In connection with the ongoing Vascepa® ANDA litigation, the Court ruled against ANDA filers' summary judgment motion that sought to end the case at this stage in their favor and ruled more in Amarin's favor to limit the scope of issues that remain at trial.

In Amarin's view, the summary judgment process and today's court ruling have strengthened Amarin's position in the litigation by eliminating from the case several potential lines of generic argument. As such, the ruling strengthens Amarin's position should it determine that case settlement is in the company's best interest. Due to the complex nature of patent litigation, we refer investors to the Court's order published today and the rulings within for further detail (available [here](#)) as we do not plan to provide any detailed assessment on the matter. We do look forward to the litigation progressing and refer investors to the risk factors section in our most recent periodic report on Form 10-Q or 10-K as filed from time to time for more detailed description of matters relevant to this litigation.

Amarin intends to continue to vigorously defend its patents.

Posted: October 29, 2019